Enanta Pharma (ENTA) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Enanta Pharma (ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
May 8, 2023 4:56 PM EDTEnanta Pharma (NASDAQ: ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Study Met Primary Endpoints of Safety and TolerabilityDose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to... More